Tag: BioCity Biopharma

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsBioCity Biopharma

Decision Notice – CIRO Hearing Panel issues its Reasons for Decision in the matter of Scott Nicolas Zurevinski

BAYOTECH SHIFTS NORTHERN CALIFORNIA HYDROGEN HUB DEVELOPMENT TO NEW SITE TO ACCELERATE IMPACT

The Wait is Over: Hard Rock Hotel & Casino Ottawa Opens with Legendary Guitar Smash and Star-Studded Celebration

Tag: BioCity Biopharma

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us